Aptevo Therapeutics (NASDAQ:APVO) Posts Earnings Results, Misses Expectations By $1.48 EPS

Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) announced its earnings results on Monday. The biotechnology company reported ($5.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.71) by ($1.48), FiscalAI reports.

Aptevo Therapeutics Price Performance

NASDAQ APVO opened at $0.59 on Monday. Aptevo Therapeutics has a 52 week low of $0.59 and a 52 week high of $25.74. The firm has a market capitalization of $1.08 million, a price-to-earnings ratio of -0.01 and a beta of 1.65. The company has a fifty day moving average of $1.59 and a two-hundred day moving average of $4.01.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded shares of Aptevo Therapeutics from a “sell (e+)” rating to a “sell (e)” rating in a report on Thursday, October 29th. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat, Aptevo Therapeutics has a consensus rating of “Sell”.

Read Our Latest Stock Report on Aptevo Therapeutics

Aptevo Therapeutics Company Profile

(Get Free Report)

Aptevo Therapeutics Inc. is a biotechnology company developing targeted immunotherapies for cancer and other serious diseases. The company is headquartered in Seattle, Washington, and was established in 2016 as a spin-off from Emergent BioSolutions. Aptevo’s research is based primarily on its ADAPTIR and ADAPTIR-FLEX antibody platforms, which are designed to create bispecific immune-cell engagers. These therapies are intended to connect immune cells with cancer cells or activate immune pathways to produce a targeted response.

Read More

Earnings History for Aptevo Therapeutics (NASDAQ:APVO)

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.